Abeona Therapeutics Doses First Patient in Phase 1/2 Trial

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Abeona Therapeutics Doses First Patient in Phase 1/2 Trial With ABO-102 Gene Therapy for Patients With Sanfilippo Syndrome Type A (MPS IIIA)

NEW YORK, NY and CLEVELAND, OH --(Marketwired - May 17, 2016) - Abeona Therapeutics Inc. ( NASDAQ : ABEO ), a clinical-stage biopharmaceutical company focused on developing products for severe and life-threatening rare genetic diseases, announced today that the first patient in a Phase 1/2 trial for ABO-102 (AAV-SGSH), a single treatment gene therapy strategy for patients with Sanfilippo syndrome type A (a.k.a Mucopolysaccharidosis Type IIIA or MPS IIIA) has been enrolled at Nationwide Children's Hospital (Columbus, Ohio).

"MPS IIIA is a profound and deadly lysosomal storage disease with no approved treatments available. Caused by a single gene defect, most of the children with this disease do not reach adulthood. This investigational gene therapy approach, delivered as a single intravenous injection to treat the whole body, represents a new treatment paradigm for addressing this relentlessly progressing disease," noted Kevin M. Flanigan, MD, principal investigator with the Center for Gene Therapy at Nationwide Children's Hospital and Professor of Pediatrics and Neurology at The Ohio State University College of Medicine. "We are grateful to the many patient foundations and parents who have supported the research needed to advance a potential treatment for this devastating unmet medical need."

"This treatment trial is the culmination of more than eighteen years of research and development, and none of it would have been possible without support from the Sanfilippo foundations," say Drs. Haiyan Fu and Doug McCarty, who lead the lysosomal disease basic research program in the Center for Gene Therapy.

The company previously announced that ABO-102 has been granted Orphan Product Designation in the USA and received the Rare Pediatric Disease Designation.

The clinical study is supported by neurocognitive testing data generated in a 25-subject MPS III Natural History Study, where all patients are through 1 year of follow up assessments.

"Abeona has demonstrated global leadership in supporting clinical and commercial development of promising gene therapies for children with Sanfilippo syndrome, and we applaud their efforts to bring these potential treatments to clinical trials," said Kathleen Buckley, President of Team Sanfilippo.

"This first-in-man gene therapy, which uses an AAV delivered by a single intravenous injection to treat the central nervous system and the peripheral disease manifestations in Sanfilippo patients, helps advance the field of gene therapy with new treatment options for these devastating diseases," noted Timothy J. Miller, PhD, Abeona's President and CEO.

About ABO-102 (AAV-SGSH): ABO-102 is an adeno-associated viral (AAV)-based gene therapy for MPS IIIA (Sanfilippo syndrome), which involves a one-time delivery of a normal copy of the defective gene to cells of the central nervous system (CNS) with the aim of reversing the effects of the genetic errors that cause the disease. After a single dose in Sanfilippo preclinical models, ABO-102 induced cells in the CNS and peripheral organs to produce the missing enzyme repaired the underlying cell pathology that is the cause of the disease. Preclinical in vivo efficacy studies in Sanfilippo syndrome have demonstrated functional benefits that are sustained for months to years after treatment. A single dose of ABO-102 significantly restored normal cell and organ function, corrected cognitive deficits, increased neuromuscular function and normalized the lifespan of animals with MPS IIIA over 100% for more than one year after treatment compared to untreated control animals. These results are consistent with studies from several laboratories suggesting AAV treatment to replace the defective gene could potentially benefit patients with Sanfilippo syndrome. In addition, safety studies conducted in animal models of Sanfilippo syndrome have demonstrated that delivery of ABO-102 is well tolerated with minimal side effects.

About Abeona: Abeona Therapeutics Inc. is a clinical stage company developing gene therapy and plasma-based products for severe and life-threatening rare genetic diseases. Abeona's lead programs are ABO-102 (AAV-SGSH) and ABO-101 (AAV-NAGLU), adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome (MPS IIIA and IIIB), respectively. We are also developing ABO-201 (AAV-CLN3) gene therapy for juvenile Batten disease (JBD); and ABO-301 (AAV-FANCC) for Fanconi anemia (FA) disorder using a novel CRISPR/Cas9-based gene editing approach to gene therapy program for rare blood diseases. In addition, Abeona is developing plasma protein therapies, including SDF Alpha™ (alpha-1 protease inhibitor) for inherited COPD, using our proprietary SDF™ (Salt Diafiltration) ethanol-free process. For more information, visit www.abeonatherapeutics.com .

About Nationwide Children's Hospital: Ranked 7th of only 10 children's hospitals on U.S. News & World Report's 2014-15 "America's Best Children's Hospitals Honor Roll" and among the Top 10 on Parents magazine's 2013 "Best Children's Hospitals" list, Nationwide Children's is one of the nation's largest not-for-profit freestanding pediatric healthcare networks providing care for infants, children and adolescents as well as adult patients with congenital disease. As home to the Department of Pediatrics of The Ohio State University College of Medicine, Nationwide Children's faculty train the next generation of pediatricians, scientists and pediatric specialists. The Research Institute at Nationwide Children's is one of the Top 10 National Institutes of Health-funded free-standing pediatric research facilities in the U.S., supporting basic, clinical, translational and health services research at Nationwide Children's. The Research Institute encompasses three research facilities totaling 525,000 square feet dedicated to research. More information is available at NationwideChildrens.org/Research.

This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, and that involve risks and uncertainties. These statements include, without limitation, our plans for continued development and internationalization of our clinical programs, management plans for the Company, and general business outlook. These statements are subject to numerous risks and uncertainties, including but not limited to continued interest in our rare disease portfolio, our ability to enroll patients in clinical trials, the impact of competition; the ability to develop our products and technologies; the ability to achieve or obtain necessary regulatory approvals; the impact of changes in the financial markets and global economic conditions; and other risks as may be detailed from time to time in the Company's Annual Reports on Form 10-K and other reports filed by the Company with the Securities and Exchange Commission. The Company undertakes no obligations to make any revisions to the forward-looking statements contained in this release or to update them to reflect events or circumstances occurring after the date of this release, whether as a result of new information, future developments or otherwise.

Company and Media Contacts: Christine Silverstein Vice President of Investor Relations Abeona Therapeutics Inc. +1 (212)-786-6212 csilverstein@abeonatherapeutics.com Andre'a Lucca Vice President of Communications & Operations Abeona Therapeutics Inc. +1 (212)-786-6208 alucca@abeonatherapeutics.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

HearUSA Expands Access with AI-Powered Hearing Aids

Updated Category News Views 130

AI Revolution in Hearing Care Look, the hearing aid industry isn't known for headlines that grab you by the throat, but HearUSA just tossed a proverbial grenade into the scene with Widex Allure AI RIC. This is more than a slight tweak in hearing tech—it's a game-changer. We're talking about on-demand AI noise management blended with Widex's renowned natural sound. It's...

Continue Reading
SiteOne Joins S&P SmallCap 600 Amid KKR's Integer Buyout

Updated Category News Views 50

Changes on the SmallCap Horizon Starting off, SiteOne Landscape Supply (NYSE: SITE) is hopping onto the S&P SmallCap 600 bandwagon. This shift activates just as the market revs up on November 19, 2026. SiteOne is stepping in as Integer Holdings Corp. (NYSE: ITGR) makes its grand exit, a move prompted by a significant acquisition by KKR & Co. Inc. (NYSE: KKR). KKR’s...

Continue Reading
Caladan Partners with Anchorage for Stronger Trading

Updated Category News Views 75

Caladan and Anchorage Unite for Asset Growth Man, partnerships might just be the secret sauce we never know we need until it’s on our plate. It's a fresh day in digital trading, and Caladan just shook things up by teaming up with Anchorage Digital, bolstering their trading and settlement capabilities to satisfy the big players. If there's one thing that's hot as a...

Continue Reading
191 Schools Honored for Academic Growth Success

Updated Category News Views 99

Celebrating Educational Progress Nationwide In a world where numbers fly off the stock tickers and translate into dollar signs in some corner office, it's refreshingly humbling to find real gains being celebrated in the educational sector. Curriculum Associates has tipped their hat to 191 schools that have done something remarkable: they've pushed students to stretch...

Continue Reading
Go NYC's Perks: Making Commutes Rewarding in NYC

Updated Category News Views 50

Go NYC's Perks: Turning Commutes into Gains I’ve seen a lot of schemes aimed at getting folks to change their travel habits, but this one from Go NYC caught my attention. These guys are trying to squeeze some extra value out of the daily grind for anyone hoofing it across the Big Apple. A new rewards program named Perks kicks off, offering all kinds of discounts and...

Continue Reading
Luxury Villa Cashback Offers Entice Travelers in November

Updated Category News Views 49

A November Bonanza for Villa Bookings Who doesn't love having a few extra bucks in their pocket, especially when they come with the allure of luxury travel? Villas of Distinction is rolling out what they call a 'November Cashback Offer,' and for those with the wallet—and wanderlust—to match, it could be a tempting proposition. Hanging the bait of up to $2,000 cashback...

Continue Reading
WirelessCar Rebrands to Reinforce Connected Mobility Vision

Updated Category News Views 122

Evolving Identity for Changing Times Let’s dive right into it—WirelessCar, a name that’s struck chords in the automotive trenches for ages, is taking a bold step by unveiling a new brand identity. Now, don’t roll your eyes just yet. This isn’t another company tapping the rebranding siren for the heck of it. We’re talking about a company that’s been in the...

Continue Reading
Stark Future Amasses €150M, Revving Up Electric Bike Dominance

Updated Category News Views 142

Well, if you've been keeping your eye on electric vehicles, this is a story that might raise those eyebrows. Stark Future, a name perhaps not buzzing on every street just yet, has gone and done it—snagged over €150 million in fresh capital. Breaking Barriers with Record-breaking Numbers Stark Future didn't just make a ripple; they caused a tsunami. This buzzing...

Continue Reading
Guangdong-US Trade: LED Screens, Beef & Trust Make Waves

Updated Category News Views 81

Guangdong's Economic Ballet with the U.S. Grab a cup of coffee, and let's unravel how Guangdong and the U.S. are tangoing their way through trade like nobody's business! Guangdong, the heavyweight champ for U.S.-China trade transactions, notched up a cool 685.27 billion yuan ($102 billion) in the first eight months of 2026. That's a healthy jump of 6.9% year on year, mind...

Continue Reading
Sovereign Crown Vault's Auction Draws Numismatic Collectors

Updated Category News Views 54

A Legendary Auction with Three Generations of Passion Coins, eh? They might just be small metallic disks to the untrained eye, but these suckers tell stories that stretch beyond any bank ledger. Sovereign Crown Vault LLC knows this, and they’re gearing up for quite the show on November 22, 2026. Their Holiday Season Kickoff Spectacular is about to lure in collectors...

Continue Reading

Top 5 Most Recently Viewed Articles

Huawei's Innovative Energy Solutions Drive Renewable Power Growth

Updated Category News Views 184

Transforming Energy Solutions with Huawei Digital Power At a prominent event in Germany, Huawei Digital Power made waves by showcasing cutting-edge solar and energy storage technologies. The company hosted an important launch event under the title "Smart PV & ESS: Powering a Grid Forming Future," emphasizing their commitment to advancing renewable energy solutions. With...

Continue Reading
Carlyle Credit Income Fund's NAV Insights and Latest Developments

Updated Category News Views 225

Understanding Carlyle Credit Income Fund's Latest NAV Report Carlyle Credit Income Fund (NYSE: CCIF) has recently unveiled its unaudited net asset value (NAV) per common share, reporting this figure as $7.64. This information was shared through a filing with the Securities and Exchange Commission, indicating the fund's current fiscal status. The announcement is important...

Continue Reading
Tuya Inc. to Announce Q4 and Fiscal Year 2025 Results Soon

Updated Category News Views 140

Tuya Inc. to Release Financial Results for Q4 and Fiscal Year 2025 Tuya Inc. (NYSE: TUYA), a prominent AI cloud platform service provider, has announced that it will share its fourth quarter and preliminary fiscal year 2025 financial results shortly after the market closes during the first week of March. This is a significant event for the company as it highlights the...

Continue Reading
Geopolitical Tensions Influence Oil Prices: Market Insights

Updated Category News Views 154

Current Oil Market Dynamics Amid Global Tensions Crude prices have shown significant resilience following earlier losses, positioning themselves for a potential third consecutive day of gains. As geopolitical tensions continue to escalate, the latest developments in the Middle East are fueling market reactions. Iran's Potential Military Actions and Market Implications...

Continue Reading
Antimony Market Growth: A Multi-Billion Dollar Future Ahead

Updated Category News Views 221

The Rising Antimony Market: A New Era of Opportunities Antimony minerals, primarily sourced from stibnite and its various forms, play a crucial role in multiple industries due to their unique properties such as flame retardancy and alloy formation. As societies continue to focus on enhancing safety in various applications, particularly in construction and automotive, the...

Continue Reading